ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
This research output has an Altmetric Attention Score of 222. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2025.
All research outputs
#215,588
of 34,306,620 outputs
Outputs from Journal of Clinical Oncology
#374
of 32,278 outputs
Outputs of similar age
#3,025
of 364,235 outputs
Outputs of similar age from Journal of Clinical Oncology
#9
of 1,006 outputs
Altmetric has tracked 34,306,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,278 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,235 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1,006 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.
